[Antihypertensives and the prevention of development of genetic hypertension in the hypertensive SHR rat].
1. The preventive effects against genetic hypertension development (GHD) of seven antihypertensive drugs chronically administered to the young SHRs from their 5th to their 13th week of age have been investigated. 2. While prazosin (20 mg/kg) and hydrochlorothiazide (6,5 and 25 mg/kg) are ineffective and while YC 93, a calcium-antagonist (10, 30, 100 mg/kg) exerts only a slight protective effect, captopril (30 and 100 mg/kg), dihydralazine (25 mg/kg) and atenolol (200 mg/kg) strongly prevent GHD. 3. Captopril and dihydralazine oppose GHD by inhibiting the progressive increase in peripheral resistance (PR) which normally occurs with ageing in SHRs. Simultaneously, these two drugs do not affect the cardiac output (CO) but increase plasma renin concentration (PRC). On the other hand, atenolol opposes GHD mainly by reducing CO and PRC while it simultaneously reinforces the progressive increase of PR with age. Captopril and atenolol, unlike dihydralazine, limit SHRs' myocardial hypertrophy. 4. After 14 weeks of treatment, arterial blood pressure (BP) of dihydralazine - and atenolol-treated animals meets control animals BP within 4 weeks whereas captopril preventive effects are still present up to 12 weeks after treatment discontinuation. Wit atenolol and captopril ther is after treatment discontinuation a good correlation between the evolution of heart weight/body weight and BP, which suggests that captopril could temporarily oppose the myocardial structural alterations which usually accompany GHD.